Jazz Pharmaceuticals Plc (JAZZ)
243.64
-0.07
(-0.03%)
USD |
NASDAQ |
Sep 02, 10:40
Jazz Pharmaceuticals Research and Development Expense (TTM) : 815.61M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 815.61M |
| March 31, 2026 | 798.08M |
| December 31, 2025 | 782.74M |
| September 30, 2025 | 809.33M |
| June 30, 2025 | 811.04M |
| March 31, 2025 | 841.80M |
| December 31, 2024 | 884.00M |
| September 30, 2024 | 860.11M |
| June 30, 2024 | 894.59M |
| March 31, 2024 | 883.10M |
| December 31, 2023 | 849.66M |
| September 30, 2023 | 805.60M |
| June 30, 2023 | 720.07M |
| March 31, 2023 | 649.88M |
| December 31, 2022 | 590.45M |
| September 30, 2022 | 573.34M |
| June 30, 2022 | 565.51M |
| March 31, 2022 | 559.16M |
| December 31, 2021 | 505.75M |
| September 30, 2021 | 442.00M |
| June 30, 2021 | 379.62M |
| March 31, 2021 | 325.84M |
| December 31, 2020 | 335.38M |
| September 30, 2020 | 341.06M |
| June 30, 2020 | 342.27M |
| Date | Value |
|---|---|
| March 31, 2020 | 325.73M |
| December 31, 2019 | 299.73M |
| September 30, 2019 | 259.00M |
| June 30, 2019 | 230.31M |
| March 31, 2019 | 224.05M |
| December 31, 2018 | 226.62M |
| September 30, 2018 | 235.95M |
| June 30, 2018 | 232.16M |
| March 31, 2018 | 216.18M |
| December 31, 2017 | 198.44M |
| September 30, 2017 | 176.60M |
| June 30, 2017 | 177.04M |
| March 31, 2017 | 175.97M |
| December 31, 2016 | 162.30M |
| September 30, 2016 | 147.59M |
| June 30, 2016 | 150.58M |
| March 31, 2016 | 139.32M |
| December 31, 2015 | 135.25M |
| September 30, 2015 | 130.36M |
| June 30, 2015 | 102.00M |
| March 31, 2015 | 94.25M |
| December 31, 2014 | 85.18M |
| September 30, 2014 | 74.43M |
| June 30, 2014 | 64.82M |
| March 31, 2014 | 53.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Avadel Pharmaceuticals Plc | 39.89M |
| Perrigo Co. Plc | 95.00M |
| GH Research Plc | 46.71M |
| Cosmo NV | 36.52M |
| Axsome Therapeutics, Inc. | 187.36M |